Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: Evidence from a meta-analysis

Lupus

Volumn 23, Issue 3, 2014, Pages 284-292

  Ni, J ^a   Qiu, L J ^a   Hu, L F ^a   Cen, H ^a   Zhang, M ^a   Wen, P F ^a   Wang, X S ^a   Pan, H F ^a   Ye, D Q ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

cancer; Meta analysis; standardized incidence rate; systemic lupus erythematosus

Indexed keywords

CANCER; META-ANALYSIS; STANDARDIZED INCIDENCE RATE; SYSTEMIC LUPUS ERYTHEMATOSUS;

FEMALE; HUMANS; INCIDENCE; LINEAR MODELS; LIVER NEOPLASMS; LUNG NEOPLASMS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; ODDS RATIO; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84894039090     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313520060     Document Type: Article

References (47)

1. Wang J, Pan HF, Su H, Li XP, Xu JH, Ye DQ. Tuberculosis in systemic lupus erythematosus in Chinese patients. Trop Doct. 2009 ; 39: 165-167
2. Knight JS, Kaplan MJ. Cardiovascular disease in lupus: Insights and updates. Curr Opin Rheumatol. 2013 ; 25: 597-605
3. Maroz N, Segal MS. Lupus nephritis and end-stage kidney disease. Am J Med Sci. 2003 ; 346: 319-323
4. Gayed M, Bernatsky S, Ramsey-Goldman R, Clarke A, Gordon C. Lupus and cancer. Lupus. 2009 ; 18: 479-485
5. Liu H, Ding Q, Yang K, Zhang T, Li G, Wu G. Meta-analysis of systemic lupus erythematosus and the risk of cervical neoplasia. Rheumatology (Oxford). 2011 ; 50: 343-348
6. Bernatsky S, Ramsey-Goldman R, Foulkes WD, Gordon C, Clarke AE. Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: A meta-analysis. Br J Cancer. 2011 ; 104: 1478-1481
7. Lin YC, Yen JH, Chang SJ, Lin YC. The age-risk relationship of haematologic malignancies in female patients with systemic lupus erythematosus: A nationwide retrospective cohort study. Lupus. 2012 ; 21: 1250-1256
8. Bernatsky S, Joseph L, Boivin JF, et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: A case-cohort study. Ann Rheum Dis. 2008 ; 67: 74-79
9. Hemminki K, Liu X, Ji J, Sundquist J, Sundquist K. Effect of autoimmune diseases on risk and survival in histology-specific lung cancer. Eur Respir J. 2012 ; 40: 1489-1495
10. Cibere J, Sibley J, Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus. 2001 ; 10: 394-400
11. Dreyer L, Faurschou M, Mogensen M, Jacobsen S. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: A long-term followup study in a Danish cohort. Arthritis Rheum. 2011 ; 63: 3032-3037
12. Ramsey-Goldman R, Mattai SA, Schilling E, et al. Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med. 1998 ; 46: 217-222
13. Furlan AD, Irvin E, Bombardier C. Limited search strategies were effective in finding relevant nonrandomized studies. J Clin Epidemiol. 2006 ; 59: 1303-1311
14. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000 ; 283: 2008-2012
15. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Ann Intern Med. 2007 ; 147: 573-577
16. Wong WC, Cheung CS, Hart GJ. Development of a quality assessment tool for systematic reviews of observational studies (QATSO) of HIV prevalence in men having sex with men and associated risk behaviours. Emerg Themes Epidemiol. 2008 ; 5: 23-23
17. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987 ; 9: 1-30
18. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959 ; 22: 19-48
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 ; 7: 177-188
20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002 ; 21: 1539-1558
21. Bernatsky S, Ramsey-Goldman, Labrecque J, et al. Cancer risk in systemic lupus: An updated international multi-centre cohort study. J Autoimmun. 2013 ; 42: 130-135
22. Ragnarsson O, Grondal G, Steinsson K. Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus. 2003 ; 12: 687-691
23. Nived O, Bengtsson A, Jönsen A, Sturfelt G, Olsson H. Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus. 2001 ; 10: 500-504
24. Sultan SM, Ioannou Y, Isenberg DA. Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology. 2000 ; 39: 1147-1152
25. Ramsey-Goldman R, Mattai SA, Schilling E, et al. Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med. 1998 ; 46: 217-222
26. Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus erythematosus. Arthritis Rheum. 1996 ; 39: 1050-1054
27. Kang KY, Kim HO, Yoon HS, et al. Incidence of cancer among female patients with systemic lupus erythematosus in Korea. Clin Rheumatol. 2010 ; 29: 381-388
28. Parikh-Patel A, White RH, Allen M, Cress R. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control. 2008 ; 19: 887-894
29. Tarr T, Gyorfy B, Szekanecz E, et al. Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: Results from a single center. Ann N Y Acad Sci. 2007 ; 1108: 76-82
30. Björnådal L, Löfström B, Yin L, Lundberg IE, Ekbom A. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol. 2002 ; 31: 66-71
31. Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 761-768
32. Ye D, Pan F, Zhang K, Li X, Xu J, Hao J. A novel single-nucleotide polymorphism of the Fcc receptor IIIa gene is associated with genetic susceptibility to systemic lupus erythematosus in Chinese populations: A family-based association study. Clin Exp Dermatol. 2006 ; 31: 553-557
33. Hansen JE, Chan G, Liu YF, et al. Targeting cancer with a lupus autoantibody. Sci Transl Med. 2012 ; 4: 157ra142-157ra142
34. Weiguang Y, Dalin L, Lidan X, et al. Association of OX40L polymorphisms with sporadic breast cancer in northeast Chinese Han population. PLoS One. 2012 ; 7: e41277 - e41277
35. Ghaderi A. CTLA4 gene variants in autoimmunity and cancer: A comparative review. Iran J Immunol. 2011 ; 8: 127-149
36. Ekblom-Kullberg S, Kautiainen H, Alha P, Leirisalo-Repo M, Julkunen H. Smoking and the risk of systemic lupus erythematosus. Clin Rheumatol. 2013 ; 32: 1219-1222
37. Bourré-Tessier J, Peschken CA, Bernatsky S, et al. Smoking is associated with cutaneous manifestations in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2013 ; 65: 1275-1280
38. Adzić TN, Pesut DP, Nagorni-Obradović LM, Stojsić JM, Vasiljević MD, Bouros D. Clinical features of lung cancer in patients with connective tissue diseases: A 10-year hospital based study. Respir Med. 2008 ; 102: 620-624
39. Siemes C, Visser LE, Coebergh JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: The Rotterdam Study. J Clin Oncol. 2006 ; 24: 5216-5222
40. Daniels CE, Jett JR. Does interstitial lung disease predispose to lung cancer?. Curr Opin Pulm Med. 2005 ; 11: 431-437
41. Rigante D, Mazzoni MB, Esposito S. The cryptic interplay between systemic lupus erythematosus and infections. Autoimmune Rev. 2014 ; 13: 96-102
42. Abbott IJ, Chang CC, Skinner MJ, et al. Development and management of systemic lupus erythematosus in an HIV-infected man with hepatitis C and B co-infection following interferon therapy: A case report. J Med Case Rep. 2009 ; 3: 7289-7289
43. Wang Z, Li M, Zeng X, Liu X. Hepatitis B virus-associated antigen deposition in renal tissue from patients with systemic lupus. J Rheumatol. 2012 ; 39: 974-978
44. Mok CC, Lau CS. Profile of sex hormones in male patients with systemic lupus erythematosus. Lupus. 2000 ; 9: 252-257
45. Mononen N, Schleutker J. Polymorphism in genes involved in androgen pathway as risk factors for prostate cancer. J Urol. 2009 ; 181: 1541-1549
46. Hoene KA, Kaufman MR, Cates JM, Chang SS. Inflammatory myofibroblastic tumor of the urinary bladder in a 27-year-old woman with systemic lupus erythematosus. Int J Urol. 2008 ; 15: 182-184
47. Plotz PH, Klippel JH, Decker JL, et al. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med. 1979 ; 91: 221-223